Happy that all questions were actually asked and answered.In...

Happy that all questions were actually asked and answered.

In terms of whether answers to my liking, well yes in terms of getting more transparency, but no in terms of sales, timeline to gen 4 hitting market.

From a new OTC category point, and in particular gen 3, it’s good that the company is getting a good read on customer demographic through retailers, and focussing on target PoS (1k, not 5K). Leads to reduced marketing and concentrated sales. This will also bode well for gen 4 at a later time, in terms of set up/ marketing.

In terms of gen 4, I didn’t like that they weren’t ready for LA (CES), or the lack of clarity to fda approval (no actual timeline, but guesstimates), wasn’t even clear if they have lodged for fda approval. Disappointed that approval now not expected until back half of year, and will hold up any OEMs. Overall I wasn’t overly impressed with Catherine, talked really quick, kept turning her zoom off and couldn’t provide certain answers. Break even now is at least 3 qtrs away I’d say. So, how do they plan to fund?

Justin also made clear that majority of OEM didn’t just want to white label OOB, but wanted additional functionality/ build….thats ok, but my question is why can’t they sign an OEM now and start building those enhancements out now under paid contract?

Justin and his team know they are under pressure now, given we asked if they were the right team to take us through to commercialisation.